Komatsu F, Kihara K
Blood Transfusion Service, School of Medicine, Tokyo Medical and Dental University.
Nihon Rinsho Meneki Gakkai Kaishi. 1995 Apr;18(2):197-206. doi: 10.2177/jsci.18.197.
NK and LAK activities of a patient who recovered from bladder transitional cell carcinoma were determined. He was diagnosed in 1980 and operations, radiations and chemotherapies were repeated until 1986. Since 1987, a relapse has not been recognized, and he is now in a tumor free state. Recently, his very high NK and LAK activities were found. The percentage of CD 16+ in his peripheral blood lymphocytes (PBL) was 52.9%, the CD 4- CD 8- CD 16+ was 26.6% (17.5% and 12.1% in control, respectively). It seems likely that his tumor free condition may be related to these high killer activities. As a high number of CD 4- CD 8- cells were included in his PBL, it was possible to generate a CD 4- CD 8(-)-LAK and compare it with the CD 8(+)-LAK. The CD 4- CD 8(-)-LAK exhibited higher killer activity which was maintained for a long period of the culture, and a strong adherence property against the cultured tumor cells. Whereas, the CD 8(+)-LAK did not show such a high level of killer activity which decreased after two weeks into the culture. However, the CD 8(+)-LAK in this patient demonstrated higher killer activity against the auto-tumor cell line compared to what occurred with the control. A type of specific killing against auto-tumor cells may be contained in his CD 8(+)-LAK, although the MHC-restrictive killing was not confirmed. It remains unclear why the killer activities increased in this patient.
对一名从膀胱移行细胞癌康复的患者的自然杀伤细胞(NK)和淋巴因子激活的杀伤细胞(LAK)活性进行了测定。他于1980年被诊断出患有该病,直到1986年反复接受手术、放疗和化疗。自1987年以来,未发现复发情况,他目前处于无瘤状态。最近,发现他的NK和LAK活性非常高。其外周血淋巴细胞(PBL)中CD16 +的百分比为52.9%,CD4 - CD8 - CD16 +为26.6%(对照组分别为17.5%和12.1%)。他的无瘤状态似乎可能与这些高杀伤活性有关。由于其PBL中包含大量CD4 - CD8 - 细胞,因此有可能产生CD4 - CD8(-)-LAK并将其与CD8(+)-LAK进行比较。CD4 - CD8(-)-LAK表现出更高的杀伤活性,在长时间培养中得以维持,并且对培养的肿瘤细胞具有很强的黏附特性。而CD8(+)-LAK未表现出如此高的杀伤活性,在培养两周后活性下降。然而,该患者的CD8(+)-LAK对自体肿瘤细胞系的杀伤活性高于对照组。尽管未证实存在主要组织相容性复合体(MHC)限制性杀伤,但他的CD8(+)-LAK中可能包含一种针对自体肿瘤细胞的特异性杀伤作用。目前尚不清楚该患者杀伤活性增加的原因。